Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.

Mostrar otras versiones (1)

Multiple myeloma is a B-cell malignancy characterized by the accumulation of plasma cells in the bone marrow and the development of osteolytic bone disease. The present study demonstrates that myeloma cells express the critical osteoclastogenic factor RANKL (the ligand for receptor activator of NF-k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Croucher, P, Shipman, C, Lippitt, J, Perry, M, Asosingh, K, Hijzen, A, Brabbs, A, van Beek, E, Holen, I, Skerry, T, Dunstan, C, Russell, G, Van Camp, B, Vanderkerken, K
Formato:	Journal article
Lenguaje:	English
Publicado:	2001

Ejemplares similares

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
por: Croucher, P, et al.
Publicado: (2001)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
por: Croucher, P, et al.
Publicado: (2000)

Zoledronic acid inhibits the development of osteolytic bone disease and increases disease free survival in a murine model of multiple myeloma.
por: Croucher, P, et al.
Publicado: (2001)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
por: Croucher, P, et al.
Publicado: (2003)

Zoledronic acid prevents the development of osteolytic bone disease and increases survival in a murine model of multiple myeloma
por: Croucher, P, et al.
Publicado: (2002)

Osteoprotegerin and the development of myeloma bone disease
por: Croucher, P, et al.
Publicado: (2004)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
por: Shipman, C, et al.
Publicado: (2000)

Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.
por: Vanderkerken, K, et al.
Publicado: (2003)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
por: Shipman, C, et al.
Publicado: (2002)

The potent bisphosphonate ibandronate does not induce myeloma cell apoptosis in a murine model of established multiple myeloma.
por: Shipman, C, et al.
Publicado: (2000)

Bone marrow endothelial cells produce osteoprotegerin: Evidence for a role in the development of myeloma bone disease
por: De Leenheer, E, et al.
Publicado: (2004)

Zoledronic acid prevents the development of myeloma bone disease and increases survival
por: Shipman, C, et al.
Publicado: (2002)

Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival.
por: Croucher, P, et al.
Publicado: (2003)

APOMINE (TM), a novel inhibitor of the meyalonate/isoprenoid pathway, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of the myeloma disease in vivo.
por: Croucher, P, et al.
Publicado: (2002)

Role of osteoprotegerin (OPG) in cancer.
por: Holen, I, et al.
Publicado: (2006)

Bisphosphonates--mechanisms of action in multiple myeloma.
por: Shipman, C, et al.
Publicado: (2000)

Bisphosphonates and in vivo models of multiple myeloma - Reply
por: Shipman, C, et al.
Publicado: (2001)

Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL.
por: Shipman, C, et al.
Publicado: (2000)

The role of osteoprotegerin in breast and prostate cancer
por: Holen, I, et al.
Publicado: (2002)

Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease.
por: De Leenheer, E, et al.
Publicado: (2002)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
por: Shipman, C, et al.
Publicado: (2002)

Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells.
por: Shipman, C, et al.
Publicado: (2003)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
por: Holen, I, et al.
Publicado: (2002)

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
por: Eaton, C, et al.
Publicado: (2004)

RANKL/RANK/osteoprotegerin system as novel therapeutic target in the treatment of primary bone tumors and osteolytic metastases
por: Anđelković Zlatibor, et al.
Publicado: (2004-01-01)

Osteocyte CIITA aggravates osteolytic bone lesions in myeloma
por: Huan Liu, et al.
Publicado: (2022-06-01)

Myeloma cells can promote osteoclastic activity rather than osteoclast recruitment in vitro; Evidence from the 5T2MM murine model of myeloma
por: Mueller, G, et al.
Publicado: (2004)

5T2MM murine myeloma cells and CD138+ve human myeloma cells promote osteoclastic activity rather than osteoclast formation in vitro
por: Mueller, G, et al.
Publicado: (2004)

Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.
por: Edwards, C, et al.
Publicado: (2007)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
por: Holen, I, et al.
Publicado: (2002)

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.
por: Eaton, C, et al.
Publicado: (2004)

Osteolytic lesions: Multiple myeloma or prostate cancer?
por: Akshitha Devaraj, MBBS, et al.
Publicado: (2023-04-01)

Preventing osteolytic lesions and osteomyelitis in multiple myeloma
por: Aiken Dao, et al.
Publicado: (2022-12-01)

Elucidation of molecular basis of osteolytic bone lesions in advanced multiple myeloma
por: Dongyeop Shin, et al.
Publicado: (2024-01-01)

Cells of the bone marrow microenvironment protect myeloma cells from apoptosis induced by TRAIL but not by agonists of TRAIL death receptors.
por: Locklin, R, et al.
Publicado: (2005)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
por: Waterman, E, et al.
Publicado: (2007)

CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation
por: Dongzheng Gai, et al.
Publicado: (2022-09-01)

Multiple myeloma presenting as a massive osteolytic lesion at the clivus
por: Domingos Sousa, et al.
Publicado: (2020-11-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
por: Dirk Hose, et al.
Publicado: (2024-12-01)

A loss of host-derived MMP-7 promotes myeloma growth and osteolytic bone disease in vivo
por: Lwin, S, et al.
Publicado: (2017)